FITC Anti-CD45 antibody [MEM-28], prediluted (ab134199)

Submit a review Q&A (1)References (3)
Flow Cytometry - FITC Anti-CD45 antibody [MEM-28], prediluted (ab134199)

    Key features and details

    • FITC Mouse monoclonal [MEM-28] to CD45, prediluted
    • Suitable for: Flow Cyt
    • Reacts with: Human
    • Conjugation: FITC. Ex: 493nm, Em: 528nm
    • Isotype: IgG1

    Overview

    • Product name

      FITC Anti-CD45 antibody [MEM-28], prediluted
      See all CD45 primary antibodies

    • Description

      FITC Mouse monoclonal [MEM-28] to CD45, prediluted

    • Host species

      Mouse

    • Conjugation

      FITC. Ex: 493nm, Em: 528nm

    • Specificity

      ab134199 reacts with all alternative forms of Human CD45.

    • Tested applications

      Suitable for: Flow Cytmore details

    • Species reactivity

      Reacts with: Human

    • Immunogen

      Human thymocytes and T lymphocytes.

    • Positive control

      • Flow Cyt: Human blood cells.

    • General notes

      Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

      Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

      We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

      In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

      We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

      Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

      Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

    Applications

    Our Abpromise guarantee covers the use of ab134199 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Abreviews Notes
    Flow Cyt Use at an assay dependent concentration.

    20 μl reagent / 100 μl of whole blood or 106 cells in a suspension.

    Target

    • Function

      Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.

    • Involvement in disease

      Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
      Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.

    • Sequence similarities

      Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
      Contains 2 fibronectin type-III domains.
      Contains 2 tyrosine-protein phosphatase domains.

    • Domain

      The first PTPase domain interacts with SKAP1.

    • Post-translational
      modifications

      Heavily N- and O-glycosylated.

    • Cellular localization

      Membrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
    • Information by UniProt

    • Database links

      • Alternative names

        • B220 antibody
        • CD 45 antibody
        • CD45 antibody
        • CD45 antigen antibody
        • CD45R antibody
        • GP180 antibody
        • L-CA antibody
        • LCA antibody
        • Leukocyte common antigen antibody
        • loc antibody
        • Ly-5 antibody
        • LY5 antibody
        • Ly5, homolog of antibody
        • Lyt-4 antibody
        • OTTHUMP00000033813 antibody
        • OTTHUMP00000033816 antibody
        • OTTHUMP00000033817 antibody
        • OTTHUMP00000038574 antibody
        • Protein tyrosine phosphatase receptor type c polypeptide antibody
        • Protein tyrosine phosphatase, receptor type C antibody
        • protein tyrosine phosphatase, receptor type, C antibody
        • Protein tyrosine phosphatase, receptor type, c polypeptide antibody
        • Ptprc antibody
        • PTPRC_HUMAN antibody
        • Receptor-type tyrosine-protein phosphatase C antibody
        • T200 antibody
        • T200 glycoprotein antibody
        • T200 leukocyte common antigen antibody
        see all

      Images

      • Flow Cytometry - FITC Anti-CD45 antibody [MEM-28], prediluted (ab134199)
        Flow Cytometry - FITC Anti-CD45 antibody [MEM-28], prediluted (ab134199)
        Flow cytometry analysis (surface staining) of human peripheral blood cells labeling CD45 with ab134199.

      References (3)

      Publishing research using ab134199? Please let us know so that we can cite the reference in this datasheet.

      ab134199 has been referenced in 3 publications.

      • Feng Y  et al. Effects of human umbilical cord mesenchymal stem cells derived from exosomes on migration ability of endometrial glandular epithelial cells. Mol Med Rep 22:715-722 (2020). PubMed: 32626977
      • Li X  et al. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. EBioMedicine 38:47-56 (2018). PubMed: 30472087
      • Liu H  et al. Human umbilical vein endothelial cell vaccine suppresses the angiogenesis of esophageal squamous cell carcinoma in a humanized mouse model. Oncol Rep 40:3006-3014 (2018). PubMed: 30132560

      Customer reviews and Q&As

      Show All Reviews Q&A
      Submit a review Submit a question

      Question

      Hi, is it possible to know the concentration of the antibody ab134199 in this pre-diluted format? I assume that the final volume is 1 mL since it is stated that the quantity is enough for 50 test and each test uses 20 microL, am I correct? Thank you for your help.

      Read More
      Answer



      I can confirm that the Anti-CD45 antibody [MEM-28] (FITC), prediluted (ab134199) is provided pre-diluted in a volume of 1 mL. This is provided at a concentration of 50 ug/ml.

      I hope this information has been helpful. Please do let me know if you have any further questions.

      Read More

      Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
      For licensing inquiries, please contact partnerships@abcam.com